October 2, 2023

error page

Business is my step

Vaxcyte Promotes Andrew Guggenhime to President and Main Economic Officer

3 min read

FOSTER Metropolis, Calif., Dec. 22, 2020 (World NEWSWIRE) — Vaxcyte, Inc., formerly acknowledged as SutroVax, a upcoming-generation vaccine enterprise looking for to increase global well being by developing exceptional and novel vaccines designed to reduce or deal with some of the most prevalent and lethal infectious disorders globally, nowadays declared the advertising of Andrew Guggenhime from Main Economic Officer and Main Enterprise Officer to President and Chief Money Officer efficient January 1, 2021. In this new purpose, Mr. Guggenhime will direct the finance, human means, company communications, trader relations, enterprise and company growth, technique, details know-how and facilities functions at Vaxcyte.

“Andrew has shown his excellent leadership abilities considering that signing up for Vaxcyte previously this calendar year, and provides considerable working experience across a extensive range of functions,” explained Grant Pickering, Main Govt Officer and Co-founder of Vaxcyte. “Today’s announcement demonstrates an evolution in our leadership structure which permits us to keep on to scale our business proficiently as we execute on our mission and advance our pipeline of novel vaccine candidates, led by VAX-24, our pneumococcal conjugate vaccine prospect built to prevent invasive pneumococcal condition.”

Mr. Guggenhime joined Vaxcyte in May well 2020, bringing extra than two a long time of finance, strategic and operational leadership expertise at equally personal and community healthcare corporations. Mr. Guggenhime joined Vaxcyte from Dermira, Inc., where he served as Main Fiscal Officer from April 2014 by means of the acquisition of the corporation by Eli Lilly and Corporation in February 2020. Prior to Dermira, Mr. Guggenhime served as Main Fiscal Officer for CardioDx, Inc., a privately held industrial-stage cardiovascular molecular diagnostics company. He also served as Chief Money Officer for Calistoga Prescribed drugs, Inc., a privately held, advancement-stage organization, which was obtained by Gilead Sciences, Inc. in 2011, and as Main Economic Officer for Facet Biotech Corporation, a biotechnology enterprise that was obtained by Abbott Laboratories in April 2010. He previously served as Chief Economic Officer of PDL BioPharma, Inc. until finally Facet Biotech was spun off from PDL BioPharma in December 2008. Prior to joining Aspect Biotech, Mr. Guggenhime served as Main Monetary Officer for Neoforma, Inc. a supplier of offer chain administration methods for the healthcare sector, which was acquired by World Healthcare Exchange, LLC in March 2006. Mr. Guggenhime commenced his profession in economic providers at Merrill Lynch & Co. and Wells Fargo & Company. He at the moment serves on the board of administrators of Metacrine, Inc., a biotechnology firm. Mr. Guggenhime holds an M.B.A. from the J.L. Kellogg Graduate University of Management at Northwestern College and a B.A. in global politics and economics from Middlebury Higher education.

About Vaxcyte
Vaxcyte is a following-era vaccine company searching for to enhance world wide wellness by creating excellent and novel vaccines built to avoid or address some of the most popular and lethal infectious diseases all over the world. The Company’s cell-no cost protein synthesis platform, comprising the XpressCFTM platform, completely licensed from Sutro Biopharma, Inc., jointly with Vaxcyte’s proprietary know-how, permits the style and design and production of protein carriers and antigens, the essential building blocks of vaccines, in methods that the Corporation believes standard vaccine systems at this time can not. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent wide-spectrum pneumococcal conjugate vaccine (PCV) currently being created for the avoidance of invasive pneumococcal sickness (IPD). Vaxcyte’s pipeline also contains VAX-XP, a PCV with an expanded breadth of coverage of at minimum 30 strains, which include recently rising strains dependable for IPD and antibiotic resistance VAX-A1, a prophylactic vaccine prospect intended to reduce Group A Strep bacterial infections and VAX-PG, a therapeutic vaccine applicant made to slow or prevent the development of periodontal ailment by concentrating on the keystone pathogen responsible for this chronic, oral inflammatory disease. For much more details, visit www.vaxcyte.com.

Get hold of:
Andrew Guggenhime, Main Money Officer & Main Small business Officer
Vaxcyte, Inc.
[email protected]

error-page.com © All rights reserved. | Newsphere by AF themes.